Maraviroc

Generic Name
Maraviroc
Brand Names
Celsentri, Selzentry
Drug Type
Small Molecule
Chemical Formula
C29H41F2N5O
CAS Number
376348-65-1
Unique Ingredient Identifier
MD6P741W8A
Background

Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was ...

Indication

Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions
CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Phase 2
Completed
Conditions
Healthy
Interventions
Drug: Maraviroc
Drug: Fosamprenavir
Drug: Ritonavir
First Posted Date
2008-10-02
Last Posted Date
2016-01-29
Lead Sponsor
Garden State Infectious Disease Associates, PA
Target Recruit Count
45
Registration Number
NCT00764465
Locations
🇺🇸

Garden State Infectious Disease Associates,PA, Voorhees, New Jersey, United States

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

Phase 4
Completed
Conditions
HIV Infection
Interventions
Drug: Placebo
Drug: Maraviroc
First Posted Date
2008-08-14
Last Posted Date
2020-08-17
Lead Sponsor
University of California, San Francisco
Target Recruit Count
45
Registration Number
NCT00735072
Locations
🇺🇸

Stanford University, Stanford, California, United States

🇺🇸

University of California San Francisco - San Francisco General Hospital, San Francisco, California, United States

🇺🇸

Rush University - Stroger Hospital of Cook County, Chicago, Illinois, United States

and more 1 locations

Maraviroc Compassionate Use

Phase 3
Withdrawn
Conditions
Human Immunodeficiency Virus Type 1
Interventions
Drug: Maraviroc
First Posted Date
2008-07-22
Last Posted Date
2016-05-04
Lead Sponsor
ViiV Healthcare
Registration Number
NCT00719823

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

First Posted Date
2008-07-16
Last Posted Date
2010-11-19
Lead Sponsor
ViiV Healthcare
Target Recruit Count
30
Registration Number
NCT00717067
Locations
🇩🇪

Pfizer Investigational Site, Muenchen, Germany

Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression

Not Applicable
Completed
Conditions
HIV Infections
Interventions
Drug: Maraviroc
First Posted Date
2008-07-03
Last Posted Date
2018-10-12
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
34
Registration Number
NCT00709111
Locations
🇺🇸

Vanderbilt Therapeutics CRS (3652), Nashville, Tennessee, United States

🇺🇸

Alabama Therapeutics CRS (5801), Birmingham, Alabama, United States

🇺🇸

Univ. of Cincinnati CRS (2401), Cincinnati, Ohio, United States

and more 26 locations

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

Phase 1
Completed
Conditions
HIV Infections
Interventions
Drug: Maraviroc
First Posted Date
2008-06-23
Last Posted Date
2012-10-23
Lead Sponsor
Rockefeller University
Target Recruit Count
8
Registration Number
NCT00703586
Locations
🇺🇸

Rockefeller University Hospital, New York, New York, United States

A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects

Phase 4
Completed
Conditions
Healthy
Interventions
Drug: Maraviroc
Drug: Raltegravir
First Posted Date
2008-04-25
Last Posted Date
2013-01-25
Lead Sponsor
ViiV Healthcare
Target Recruit Count
18
Registration Number
NCT00666705
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

First Posted Date
2007-10-01
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
517
Registration Number
NCT00537394
Locations
🇺🇸

Children's National Med. Ctr. ATN CRS, Washington, District of Columbia, United States

🇺🇸

Univ. of Rochester ACTG CRS, Rochester, New York, United States

🇺🇸

UCLA CARE Center CRS, Los Angeles, California, United States

and more 61 locations

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

First Posted Date
2007-09-06
Last Posted Date
2015-03-09
Lead Sponsor
Rockefeller University
Target Recruit Count
40
Registration Number
NCT00525733
Locations
🇺🇸

Rockefeller University, New York, New York, United States

🇺🇸

The Rockefeller University, New York, New York, United States

Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

First Posted Date
2007-07-04
Last Posted Date
2019-01-30
Lead Sponsor
ViiV Healthcare
Target Recruit Count
16
Registration Number
NCT00496782
Locations
🇨🇦

Pfizer Investigational Site, Montreal, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy